title: Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
abstract: Integrins play a crucial role in the development and maintenance of the inflammatory process in patients with inflammatory bowel disease. Vedolizumab is a humanized monoclonal antibody with a predominantly gastrointestinal effect. It specifically inhibits leukocyte integrin α4β7, thus preventing its interaction with mucosal vascular addressin cell adhesion molecule 1(MAdCAM-1), which is involved in the migration of lymphocytes from the blood stream to the intestinal tissue. Vedolizumab is indicated in the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adult patients with poor response, loss of response, or intolerance to conventional treatment or to tumour necrosis factor alpha (TNF-α) antagonists. This review presents the most relevant clinical outcomes of vedolizumab in the treatment of patients with ulcerative colitis.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD). Electronic address: eugenidomenech@gmail.com.
authors.forename: Eugeni
authors.initials: E
authors.lastname: Domènech
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD).
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D002448:Cell Adhesion / Q000187:drug effects; D015815:Cell Adhesion Molecules; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004311:Double-Blind Method; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D009088:Mucoproteins / Q000378:metabolism; D015337:Multicenter Studies as Topic; D009928:Organ Specificity; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents; D007136:Immunoglobulins; D016023:Integrins; C504265:MADCAM1 protein, human; D009088:Mucoproteins; C071777:integrin alpha4beta7; C543529:vedolizumab
keywords: Adhesion molecules; Colitis ulcerosa; Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Integrinas; Integrins; Moléculas de adhesión; Ulcerative colitis; Vedolizumab